Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA
Angelini Pharma wrapped up its $4.1 billion takeover of Catalyst Pharmaceuticals, Inc. before the U.S. market opened Wednesday, taking the rare-disease drugmaker private. That price tag overstates the real cost. Stripping out Catalyst’s estimated net cash, the deal gives an enterprise value around $3.24 billion, or about 9 times expected 2026 adjusted EBITDA—a measure of operating profit before interest, tax, depreciation and amortization.
